Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology WinInvestors Business Daily • Friday
Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug SalesInvestopedia • Friday
Bristol Myers (BMY) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • Friday
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research • Friday
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costsCNBC • Friday
2 High-Yield Dividend Stocks Billionaires Are Buying. Are They Right for You?The Motley Fool • Thursday
Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings?Zacks Investment Research • Tuesday
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCCZacks Investment Research • Monday
Is a Massive S&P 500 Sell-Off Starting? – Buy 4 Safe Passive Income Dividend Stocks Now24/7 Wall Street • 07/19/24
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/19/24